Contribute Try STAT+ Today

WASHINGTON — Purdue Pharma, the embattled opioid maker, has quietly split ways with PhRMA, the powerful lobbying organization charged with representing the drug industry in Washington.

The break is the latest demonstration that the drug maker, which has filed for bankruptcy and is inundated by lawsuits across the country for its role in marketing OxyContin, is retreating from attempts to influence federal drug policy or restore its reputation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • If only all self-serving, unscrupulously abusive, and fully greed-fired drug companies would follow suit, the Big Pharma Lobbyist Machine would become extinct. When that is accomplished, mark that glorious day as a new National Holiday – for everyone in the US !! Of course Purdue’s lobby-stop is lack-of-money related – but who cares?

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy